ZOLYMBUS (glucoRx) is a long-acting insulant used to treat diabetes mellitus. As a biosimilar product, its supply chain comprises multiple manufacturers and authorized distributors across different regions. The primary suppliers include:
Elucidate (formerly Wockhardt UK): Licensed producer in Europe, authorized by regulatory agencies to distribute ZOLYMBUS.
Sandoz (Novartis division): Approved biosimilar manufacturer, primarily in the U.S. and Europe.
Biocon: Produces biosimilar insulins, including formulations comparable to ZOLYMBUS, primarily in India.
Gan & Lee: Chinese manufacturer approved for local distribution.
Pfizer: Historically involved in biosimilar insulin development; active in some markets with similar products.
Market distribution by geographic region
Region
Key Suppliers
Notes
Europe
Elucidate, Biocon, Sandoz
Approved biosimilar ZOLYMBUS variants
United States
Sandoz, Pfizer (pending approvals)
Sandoz has marketed biosimilars under different names
Asia-Pacific
Gan & Lee, Biocon, local generic manufacturers
Local distribution in China, India, and broader Asia
Latin America
Local distributors, some licensed biosimilar producers
Filled with imported biosimilar insulin analogs
Supply chain dynamics
Regulatory approval influences supplier diversity. The European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) approve specific biosimilar manufacturers based on rigorous review.
Manufacturing capacity: Companies like Sandoz and Biocon operate large-scale production facilities in Europe, India, and the U.S.
Pricing pressures: Biosimilar market competitiveness influences supplier selection, with firms such as Biocon often underpricing innovator products.
How do manufacturing and licensing impact supply?
Regulatory approval is mandatory for suppliers to distribute ZOLYMBUS legally. Only manufacturers with approved biosimilar status can supply officially.
Manufacturing quality standards include compliance with Good Manufacturing Practices (GMP). This limits the field to top-tier facilities like those operated by Sandoz and Biocon.
Licensing agreements govern distribution rights across regions. For instance, Western markets typically require licensing from patent holders or biosimilar patent licensors.
What are alternative sources or substitutes?
Biosimilar competitors such as Lili (Lilly), Eli Lilly's biosimilar versions, and Eli Lilly's Humalog are often substitutes in markets where ZOLYMBUS is not available.
Key considerations for procurement
Regulatory compliance: Confirm the supplier has approvals from relevant authorities (EMA, FDA).
Supply stability: Evaluate manufacturing capacity and geographic diversification.
Pricing: Biosimilar competition drives prices down but depends on local reimbursement policies.
Quality assurance: Confirm adherence to GMP standards and licensing status.
Supply chain risks
Regulatory delays: Approval processes can prohibit or delay new suppliers.
Manufacturing disruptions: Raw material shortages or quality issues can lead to supply interruptions.
Patent litigations: Legal disputes may restrict certain suppliers or delay market entry.
Summary table: Major ZOLYMBUS suppliers and markets
Supplier
Region of operation
Licensing status
Estimated monthly output (units)
Notes
Elucidate
Europe
Approved
100 million+
Established European supplier
Sandoz
Global
Approved
120 million+
Largest biosimilar insulin producer
Biocon
India, broader Asia
Approved
80 million+
Major biosimilar producer in developing markets
Gan & Lee
China
Licensed
50 million+
Regional focus, expanding globally
Key Takeaways
ZOLYMBUS's primary suppliers include Elucidate, Sandoz, Biocon, and Gan & Lee.
Supplier approval hinges on regulatory clearance, manufacturing capacity, and licensing.
The biosimilar insulins market is highly competitive, with key players operating across multiple regions.
Supply chain risks include regulatory delays, manufacturing disruptions, and legal disputes.
FAQs
Which companies are authorized to produce ZOLYMBUS?
Sandoz, Biocon, and Elucidate are primary authorized biosimilar producers with regulatory approval in different markets.
Can I source ZOLYMBUS directly from manufacturers?
Only if authorized distributors or procurement channels are established, and the supplier holds the appropriate licensing and GMP certification.
What regions have the highest availability of ZOLYMBUS?
Europe, India, and select Asian markets have the most accessible supply due to local approvals and manufacturing facilities.
Are biosimilar suppliers reliable?
Major players like Sandoz and Biocon adhere to strict quality standards, but supply continuity depends on regional regulatory environments and manufacturing robustness.
Is there a risk of shortages?
Yes, supply disruptions can occur due to manufacturing issues, legal challenges, or regulatory delays, especially in markets where licensing is recent or complex.
References
European Medicines Agency. (2022). Biosimilar insulin products: approval status.
U.S. Food and Drug Administration. (2023). Biosimilar insulin approvals and regulations.
MarketWatch. (2022). Global biosimilar insulin market analysis.
Biocon. (2022). Product pipeline and manufacturing capabilities.
Sandoz. (2023). Biosimilar insulin manufacturing and approvals.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
